Development of Animal Models and Related Biological Materials for Research (R21 Clinical Trial Not Allowed)
Issued by National Institutes of Health · via Grants.gov — US federal funding opportunities
- Published
- 15 Nov 2024
- Closes
- 7 Jan 2028, 23:59 UTC
- Value
- USD 2,00,000
- Reference
- PAR-25-273
- Location
- United States
- Sector
- Healthcare & Pharma
Details
This notice of funding opportunity (NOFO) encourages innovative research to develop, improve, characterize, and preserve animal models as well as animal model related biological materials, technologies, and new approach methodologies (NAMs) for studies relevant to human health and disease. This NOFO also seeks projects aimed at improving the diagnosis and control of diseases that could confound or interfere with animal use in biomedical research. The proposed project must have broad applicability to multiple NIH Institutes or Centers (ICs) to align with the NIH-wide mission of the Office of Research Infrastructure Programs (ORIP). The proposed studies must include animal models and explore multiple body systems or multiple categories of diseases. Applications that develop models focused on a specific disease or area of research, or only propose studies primarily relevant to a single NIH IC, will be considered not acceptable to this NOFO and will be withdrawn. Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Estimated total programme funding: USD 200000
CFDA number(s): 93.351
Federal funding opportunity published on Grants.gov. Applications are submitted through Grants.gov — see the official listing.
Before you bid on this tender
A quick checklist to help you decide whether to bid and prepare a compliant submission for this healthcare & pharma opportunity. Always verify the details on the official source.
- Confirm the exact closing date and time (and time zone) on the official portal — deadlines are strict and can be revised by a corrigendum.
- Read the full notice and every attached document, including the scope, specifications and any bill of quantities or terms of reference.
- Check the eligibility criteria — prior similar experience, annual turnover, certifications and registrations — and make sure you qualify before investing effort.
- Prepare any earnest-money deposit (EMD) or bid security and the required formats early; missing or wrongly-formatted documents are a common cause of rejection.
- Note how bids must be submitted (online or physical), in what format, and whether a digital signature or portal registration is required.
- Watch for corrigenda and clarifications right up to the deadline — requirements and dates can change.
More Healthcare & Pharma tenders
- Prevention AssistantMENTOR · Venezuela
- Annual maintenance contract for the Civil work in Centenary Super Specialty building S.S. Hospital, IMS, BHU, Varanasi.Banaras Hindu University · India
- Accessories for Multipara Monitor Model Ultima Prime Make BPLDr. Ram Manohar Lohia Hospital · Procurement Section · India
- CAMC for HPLC SystemCouncil of Scientific and Industrial Research · IGIB-Delhi - CSIR · Purchase-IGIB - CSIR · India
- Acquérir 6 véhicules de transport adaptés pour l'acheminement des produits de santé dans les 6 wilayasUGP SWEDD
FreeTender mirrors this notice for reference. Verify the details and bid on the official portal.
Verify & apply on the official portal →